1	Application No.	Applicant(s)	
Notice of Allowability	08/704,159	WILLIAMS ET AL.	
	Examiner	Art Unit	
•	Bao Qun Li	1648	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.			
1. \square This communication is responsive to $\underline{9/22/04}$.			
2. The allowed claim(s) is/are <u>113-117, 121, 135</u> .			
3. The drawings filed on are accepted by the Examine	r. '		•
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(
Attachment(s) 1. ☑ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	5. ☐ Notice of Informal F 6. ☑ Interview Summary Paper No./Mail Da 7. ☑ Examiner's Amendr 8. ☑ Examiner's Stateme 9. ☐ Other	(PTO-413), te <u>10/12/2004</u> . ment/Comment	,

Application/Control Number: 08/704,159

Art Unit: 1648

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Frank J. Uxa on 10/12/2004.

The application has been amended as follows:

Canceled claims 120 and 135.

Claim 113 (current amended). In line 1 after "toxin" inserted --- type A --- In line 4 after "vector" deleted "includes a weak inducible promoter relative to a T7" inserted --- is T7lac ---

Claims 113-117, 121 and 124 are allowed.

2. The following is an examiner's statement of reasons for allowance: Applicants insist that the claimed method is an unexpected result for producing a recombinant botulinum toxin type A in a soluble form by using T7lac promoter in a prokaryotic host cell because the state of art teaches away from the claimed invention in that T7lac promoter can be used for expressing large quantity of recombinant protein, however, most of the protein is expressed and accumulated in insoluble inclusion bodies as evidenced by Nassau et al. (J. Bacterio. 1996, Vol. 178, No. 4, pp. 1047-1052, see abstract) and Hill et al. (Arch. Biochem. Biophy. 1996, Vol. 336, No. 2, pp. 283-289, see abstract).

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Application/Control Number: 08/704,159

Art Unit: 1648

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bao Qun Li whose telephone number is 571-272-0904. The examiner can normally be reached on 7:00 am to 3:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Bao Qun Li

10/16/2004

JAMES HOUSEL

SUPERVISORY PATENT EXAMINER